Posts

Kura Reports Durable Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve ccRCC at KCRS 2026

on

Huyabio scores with Opdivo combo in 'milestone' skin cancer trial

on

Bristol Myers details Krazati confirmatory study failure in colorectal cancer

on

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501 in Relapsed/Refractory B‑Cell Non‑Hodgkin Lymphoma

on

Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics-induced CD8 T cell responses and clinical activity

on

WOW!: RevMed and Tango’s pancreatic cancer combo achieves 92% response

on

Gilead highlights Tubulis ADC ovarian cancer data as validation of buyout decision

on

Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti

on

Immunome’s desmoid tumor drug varegacestat posts landmark Phase 3 results, setting up a potential challenge to Merck KGaA’s Ogsiveo

on

AstraZeneca’s dual-targeting CAR-T AZD0120 shows similar response rates in Western and Chinese patients

on

Nuvalent Shares Positive Phase 1/2 ALK Inhibitor Data Rivaling Pfizer’s Lorbrena in Lung Cancer

on

Cogent Biosciences Soars on Positive Phase 3 PEAK Results in Gastrointestinal Stromal Tumors (GIST)

on

Moderna Unveils Promising mRNA-4359 Cancer Antigen Therapy Data in Melanoma Ahead of ESMO 2025

on

PMV Pharma's p53 Drug Shows Effect in Ovarian Cancer, but Financial Challenges Loom

on

ImmuneOnco and Instil Bio's PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial

on

Replimune's Shares Plunge After FDA Rejects Melanoma Drug Application

on

Nuvalent Reports Positive Pivotal Data for ROS1-Targeted Lung Cancer Drug; Rolling FDA Submission Planned

on

J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial

on